Ikarian Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Ikarian Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-650,000	Closed	-$3.12M	–	340
2020 Q4	$3.12M	Buy	650,000 +250,000	+63%	+$1.26M	0.14%	126
2020 Q3	$2.33M	Sell	400,000 -76,900	-16%	-$460K	0.17%	107
2020 Q2	$3.22M	Sell	476,900 -298,000	-38%	-$2.26M	0.26%	88
2020 Q1	$4.93M	Buy	774,900 +261,200	+51%	+$2.1M	0.37%	64
2019 Q4	$5.36M	Buy	+513,700	New	+$3.74M	0.87%	37

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Ikarian Capital's CLVS Position: Q4 2022 in Review

Ikarian Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 361,518 shares — an estimated $430K sold.

Ikarian Capital first reported a position in CLVS in Q1 2020 and held it in 11 quarters. The position peaked at $6.55M in Q2 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Ikarian Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Ikarian Capital sold 361,518 Clovis Oncology, Inc. shares in Q4 2022, an estimated $430K.
Ikarian Capital first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 11 quarters.
Ikarian Capital's Clovis Oncology, Inc. position peaked at $6.55M in Q2 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.